Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Parkinson's Disease: Treatment

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...

Parkinson's Disease: Overview

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...

Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists

Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists

Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...

Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship

Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship

Cholinergic agonists or cholinomimetics mimic the action of acetylcholine to stimulate the parasympathetic nervous system. They are categorized into direct-acting and indirect-acting agents. The direct-acting cholinergic drugs induce the parasympathetic response by directly binding to the muscarinic or nicotine receptors. In comparison, the indirect-acting cholinergic drugs prevent acetylcholine hydrolysis, indirectly contributing to the extended parasympathetic response.
The direct-acting...

Drugs Acting on Autonomic Ganglia: Blockers

Drugs Acting on Autonomic Ganglia: Blockers

Ganglionic blockers inhibit autonomic activity by blocking nicotinic receptors in the autonomic ganglia, suppressing impulse transmission. These blockers lack selectivity between sympathetic and parasympathetic ganglia and are ineffective as neuromuscular junction antagonists. They can be categorized into two groups:

Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship

Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship

Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Dairy Cattle and the Iconic Autochthonous Cattle in Northern Portugal Are Reservoirs of Multidrug-Resistant <i>Escherichia coli</i>.

Antibiotics (Basel, Switzerland)·2025

Same author

A Cyclam Salt as an Antifungal Agent: Interference with <i>Candida</i> spp. and <i>Cryptococcus neoformans</i> Mechanisms of Virulence.

Antibiotics (Basel, Switzerland)·2024

Same author

Cognitive-Enhancing Effects of Acetylcholine Receptor Agonists in Group-Housed Cynomolgus Monkeys Who Drink Ethanol.

The Journal of pharmacology and experimental therapeutics·2023

Same author

Assessment of biofilm, enzyme production and antibiotic susceptibility of bacteria from milk pre- and post-pasteurization pipelines in Algeria.

International journal of food microbiology·2023

Same author

Unveiling the Relevance of the Oral Cavity as a <i>Staphylococcus aureus</i> Colonization Site and Potential Source of Antimicrobial Resistance.

Pathogens (Basel, Switzerland)·2023

Same author

Molecular mechanism of biased signaling at the kappa opioid receptor.

Nature communications·2023

Search research articles

Related Experiment Video

Updated: Jun 5, 2026

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

Nicotinic receptor agonists decrease L-dopa-induced dyskinesias most effectively in partially lesioned parkinsonian

Luping Z Huang¹, Carla Campos, Jason Ly

¹Center for Health Sciences, SRI International, 333 Ravenswood Ave, CA 94025, USA.

Neuropharmacology

|January 15, 2011

Summary

This summary is machine-generated.

Nicotinic receptor agonists show promise in reducing L-dopa-induced abnormal involuntary movements (AIMs) in Parkinson's disease models. Selective agonists were most effective in partially damaged dopamine systems, suggesting specific receptor targets for treating dyskinesias.

More Related Videos

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

MALDI Imaging Mass Spectrometry of Neuropeptides in Parkinson's Disease

MALDI Imaging Mass Spectrometry of Neuropeptides in Parkinson's Disease

Published on: February 14, 2012

Related Experiment Videos

Last Updated: Jun 5, 2026

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

MALDI Imaging Mass Spectrometry of Neuropeptides in Parkinson's Disease

MALDI Imaging Mass Spectrometry of Neuropeptides in Parkinson's Disease

Published on: February 14, 2012

Area of Science:

Neuroscience
Pharmacology
Movement Disorders

Background:

Levodopa (L-dopa) is a primary treatment for Parkinson's disease (PD), but often induces dyskinesias, or abnormal involuntary movements (AIMs).
Limited therapeutic options exist for managing L-dopa-induced dyskinesias (PDD).
Previous studies indicated nicotine's potential to reduce L-dopa-induced AIMs in animal models.

Purpose of the Study:

To investigate the antidyskinetic effects of nicotinic acetylcholine receptor (nAChR) agonists in a rodent model of Parkinson's disease with varying striatal damage.
To elucidate the role of specific nAChR subtypes in mediating the antidyskinetic actions of nicotine.

Main Methods:

Utilized unilateral 6-hydroxydopamine (6-OHDA) lesioned rats with near-complete (>99%) or partial striatal dopamine depletion.
Administered L-dopa to induce AIMs and tested the effects of varenicline (multi-nAChR agonist) and 5-iodo-A-85380 (A-85380, selective α4β2* and α6β2* nAChR agonist).
Assessed AIMs severity and L-dopa's antiparkinsonian efficacy.

Main Results:

In rats with near-complete lesions, varenicline showed no significant effect, while A-85380 reduced AIMs by 20%.
In rats with partial lesions, both varenicline and A-85380 significantly reduced AIMs by 40-50%.
Neither drug impaired the therapeutic antiparkinsonian effect of L-dopa.

Conclusions:

Selective nAChR agonists effectively reduce L-dopa-induced dyskinesias, with optimal efficacy observed in models of partial striatal dopamine damage.
Presynaptic dopamine terminal α4β2* and α6β2* nAChRs are crucial for the antidyskinetic effects of nicotine-like drugs.
These findings support the development of nAChR-targeted therapies for managing PDD, a common complication of dopamine replacement therapy.